Published in Oncol Rev on August 30, 2013
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med (2010) 27.12
One-time general consent for research on biological samples. BMJ (2006) 6.14
Perceptions of cancer patients and their physicians involved in phase I trials. J Clin Oncol (1995) 5.86
Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. JAMA (2004) 4.36
Clinical trials and medical care: defining the therapeutic misconception. PLoS Med (2007) 3.77
Descriptions of benefits and risks in consent forms for phase 1 oncology trials. N Engl J Med (2002) 3.62
Impact and perceptions of mandatory tumor biopsies for correlative studies in clinical trials of novel anticancer agents. J Clin Oncol (2006) 3.31
Trends in the use and role of biomarkers in phase I oncology trials. Clin Cancer Res (2007) 3.24
Risks and benefits of phase 1 oncology trials, revisited. N Engl J Med (2005) 2.98
Patients' decision-making process regarding participation in phase I oncology research. J Clin Oncol (2006) 2.72
Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res (2010) 2.44
Use of research biopsies in clinical trials: are risks and benefits adequately discussed? J Clin Oncol (2012) 2.43
Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21. Clin Lung Cancer (2006) 2.14
Strategic physician communication and oncology clinical trials. J Clin Oncol (1999) 2.00
Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies. J Natl Cancer Inst (2006) 1.83
Participants in phase 1 oncology research trials: are they vulnerable? Arch Intern Med (2008) 1.74
Envisioning the future of early anticancer drug development. Nat Rev Cancer (2010) 1.67
The US Food and Drug Administration perspective on cancer biomarker development. Nat Rev Cancer (2006) 1.67
Are we taking without giving in return? The ethics of research-related biopsies and the benefits of clinical trial participation. J Clin Oncol (2006) 1.63
Impact of quality of life on patient expectations regarding phase I clinical trials. J Clin Oncol (2000) 1.47
An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics. Clin Cancer Res (2010) 1.44
Ethics of mandatory research biopsy for correlative end points within clinical trials in oncology. J Clin Oncol (2010) 1.42
Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation. Clin Cancer Res (2001) 1.42
Expectations of benefit in early-phase clinical trials: implications for assessing the adequacy of informed consent. Med Decis Making (2008) 1.34
Reasons given by patients for participating, or not, in Phase 1 cancer trials. Eur J Cancer (2011) 1.18
Performing nondiagnostic research biopsies in irradiated tissue: a review of scientific, clinical, and ethical considerations. J Clin Oncol (2008) 1.12
Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small-cell lung cancer. Lung Cancer (2004) 1.06
Sequential research-related biopsies in phase I trials: acceptance, feasibility and safety. Ann Oncol (2011) 1.04
Two concepts of therapeutic optimism. J Med Ethics (2011) 1.02
Outcomes of research biopsies in phase I clinical trials: the MD anderson cancer center experience. Oncologist (2011) 1.02
Hope and coping in patients with cancer diagnoses. Cancer Nurs (2004) 1.00
Performance of biopsies in clinical research. J Clin Oncol (2007) 0.91
Toward improved understanding of the ethical and clinical issues surrounding mandatory research biopsies. J Clin Oncol (2012) 0.90
Participants in phase 1 oncology research trials are vulnerable. Arch Intern Med (2008) 0.77